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We have recently clarified that nicotinic acetylcholine receptors (nAChRs) 
expressed in the thalamus play an important role in antiallodynic effects 
produced by the nAChR agonist, 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine 
(5IA). The present study aimed to reveal the in vivo relationship between 




We partially ligated the sciatic nerve of a rat to induce neuropathic pain. 
Antiallodynic effects were evaluated at 15, 30, 60, and 90 min after 
intracerebroventricular (i.c.v.) administration of multiple doses (1–100 nmol) of 
5IA by the von Frey filament test. Receptor occupancy rates were measured by 
autoradiography at 15 and 90 min after administration. Antiallodynic effects of 
repetitive treatment of 5IA (5 and 50 nmol) were also examined.  
A significant and dose-dependent antiallodynic effect was observed 15 min after 
administration. It showed a good correlation with receptor occupancy rates (r = 
0.97), indicating the binding of 5IA to nAChRs expressed in the thalamus 
involved in the antiallodynic effect. Five, 50, and 100 nmol of 5IA occupied the 
thalamic nAChRs until 90 min after administration, while the antiallodynic 
effect diminished. Five nanomoles of 5IA (which occupied 40% of thalamic 
nAChRs) showed a significant antiallodynic effect (percentage of the maximal 
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possible effect (%MPE): 35 ± 7) after the second administration, while 50 nmol 
of 5IA (which occupied 80% of thalamic nAChRs) did not (%MPE: 7 ± 1) . 
These findings suggest that not clearance of 5IA but desensitization of nAChRs 





Nicotinic acetylcholine receptors (nAChRs) are a family of ligand-gated ion 
channels that regulate neurotransmission in the central and peripheral nervous 
systems. The central nAChRs are pentameric complexes consisting of various α 
(α2–α10) and β (β2–β4) subunits, with the heteromeric α4β2 isoform being the 
most abundant nAChR subtype in the mammalian brain (Dwoskin et al., 2009). 
Indeed, it has been suggested that at least 90% of neuronal nAChRs in the brain 
are α4β2 nAChRs (Flores et al., 1992; Lindstrom et al., 1995). The homomeric 
α7 isoform is the second most abundant nAChR subtype in the brain. These 
receptors are implicated not only in various brain functions, such as cognition, 
memory and learning, but also in many diseases, e.g., Alzheimer ’s disease 
(Court et al., 2000; Paterson and Nordberg, 2000). Thus, clarifying how nAChRs 






I]5IA) is one 
of the tools that can make such researches possible. This compound is a 
radiolabeled form of 5IA, which is a derivative of A-85380, iodinated at the 
5-position of the pyridine ring. [
123/125
I]5IA is a nAChR imaging probe with high 
selectivity and specificity for α4β2 nAChRs not only in rodents but also in 
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humans (Mamede et al., 2004; Ogawa et al., 2009), and it has a relatively good 
safety profile (Brasic et al., 2009; Ueda et al., 2004). In fact, some 
methodologies have been developed for the noninvasive imaging and 
quantification of nAChR density in vivo (Fujita et al., 2003; Mamede et al., 
2004; Staley et al., 2005). By using these techniques, changes in the nAChR 
density of living humans have been found, e.g., decrease in Alzheimer ’s disease 
and Parkinson’s disease (Mitsis et al., 2009b; Oishi et al., 2007); age-related 
decline (Mitsis et al., 2009a); and upregulation and recovery after smoking 
cessation (Mamede et al., 2007; Mukhin et al., 2008). 
Moreover, 5IA acts as a nAChR agonist, and a neuroprotective effect and 
an analgesic effect of 5IA have been reported (Ueda et al., 2008; Ueda et al., 
2010). The biodistribution and metabolism of [
123/125
I]5IA are both similar to 
those of 5IA because [
123/125
I]5IA is a radiolabeled analogue of 5IA. Accordingly, 
pharmacokinetics, receptor occupancy, and binding potential (an index of 
nAChR density) of 5IA can be easily measured using [
123/125
I]5IA. Studies using 
5IA have the advantage of pharmacodynamic effects being directly compared to 
the pharmacokinetic profile of the compound. 
Recently, we demonstrated an upregulation of thalamic nAChRs in a 
model of chronic pain. Moreover, we found that intrathalamic administration of 
5IA attenuated tactile allodynia in a dose-dependent manner and that the 
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blockade of thalamic nAChRs reduced the antiallodynic effect of 5IA 
administered by an intracerebroventricular (i.c.v.) route (Ueda et al., 2010). 
These findings indicate that thalamic nAChRs are potentially where the 
antinociceptive action of 5IA is produced. Therefore, we focused on nAChRs in 
the thalamus and aimed to reveal the in vivo relationship between thalamic 
nAChR occupancy rates and antiallodynic effects in a rat model of neuropathic 
pain. Since it has been reported that A-85380 acts on both peripheral and central 
nAChRs, and shows antiallodynic effects after i.p. administration (Rueter et al., 
2003), we adopted i.c.v. administration instead of systemic administration in 
order to evaluate the antiallodynic effect associated only with thalamic nAChRs. 
The similarity between 5IA and [
123/125
I]5IA has a great advantage that enables 
us to evaluate the relationship between pharmacological effects and receptor 
occupancy directly and with great precision. In the present study, we measured 




MATERIALS AND METHODS 
Animals 
Animal experiments were conducted in accordance with our institutional 
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guidelines. Experimental procedures were approved by the Kyoto University 
Animal Care Committee. 
Male Sprague-Dawley rats weighing 200–250 g were purchased from 
Japan SLC Co., Ltd. (Hamamatsu, Japan). The animals were kept at a constant 




 Iodine-125 radionuclide was purchased from PerkinElmer, Inc (Waltham, 
MA). (–)-Cytisine was purchased from Sigma-Aldrich, Co (St. Louis, MO). 5IA 
and [
125
I]5IA were synthesized according to a previously published method (Saji 
et al., 2002). The specific radioactivity of [
125
I]5IA was determined from the UV 
absorbance at 254 nm as more than 55 GBq/μmol (the limit with detection of 
this method). Drugs were administered to animals as physiological saline 
solution. All other chemicals used were of reagent grade. 
 
Surgical operation 
Neuropathic pain was established by a partial sciatic nerve ligation (PSL) 
according to a previously published method (Seltzer et al., 1990; Ueda et al., 
2010). Under sodium pentobarbital anesthesia (50 mg/kg, intraperitoneally 
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[i.p.]), the right sciatic nerve was exposed just distal to the branch leading to the 
posterior biceps femoris/semitendinosus muscles. A 7-0 silk suture was inserted 
into the nerve and tightly ligated so that the dorsal 1/3 to 1/2 of the nerve was 
trapped in the ligature. 
 After recovery from PSL surgery, the rats were implanted with a stainless 
steel guide cannula (outside diameter [o.d.] 0.7 mm, inside diameter [i.d.] 0.38 
mm) under sodium pentobarbital (50 mg/kg, i.p.) anesthesia for i.c.v. 
administration. The rats were placed into a stereotaxic apparatus (SR-5, 
Narishige Co., Ltd., Tokyo, Japan) and unilaterally implanted with a guide 
cannula above the lateral ventricle (0.8 mm posterior and 1.5 mm lateral to 
bregma, 2.0 mm below the outer surface of the skull). The stereotaxic 
coordinates were guided by referring to the Atlas of Paxinos and Watson 
(Paxinos and Watson, 2005). The guide cannula was held firmly in place by 
dental acrylic cement. After surgery, the rats were individually returned to their 
cages and left to recover for 5 days or more until the following experiments. 
 
von Frey filament test 
Just before and 2 weeks after PSL, tactile sensitivity was measured using 
a calibrated von Frey filament ranging from 0.04–26 g (North Coast Medical, 
Morgan Hill, CA) as described previously (Ueda et al., 2010). Briefly, the 
 10 
animals were individually placed on an elevated wire mesh floor for testing. 
After a habituation period of 15–30 min, a tactile stimulus was applied to the 
middle plantar of the each paw by placing the von Frey filament perpendicular to 
the surface of the paw. The filament was held in this position with enough force 
to cause a slight bend. One trial involved 10 applications of filaments every 1 to 
2 sec. The threshold was determined to be the filament of the lowest stiffness, at 
which the rat responded (quick paw flick) in one or more of the trials. Rats that 
showed a lower threshold than preoperatively were considered to be 
demonstrating allodynia, and they were used in the following studies. 
 
Effect of 5IA on tactile allodynia 
 For single administration, an injection cannula (o.d. 0.35 mm, i.d. 0.18 
mm) was inserted 5.0 mm below the surface of the skull along the guide cannula. 
Various concentrations of 5IA (1, 3, 5, 10, 50, and 100 nmol dissolved in 5 μL of 
saline) or vehicle were then infused at 5 μL/rat with a constant rate of 10 μL/min 
by using a microsyringe pump (EP-60, Eicom Corporation, Kyoto, Japan). Each 
group consisted of four to six animals. The injection cannula was retained in 
place for an additional 1 min to prevent a backflow of the drugs. Just before and 
15, 30, 60, and 90 min after administration, tactile allodynia of the ligated paws 
was evaluated using the von Frey filament test. The results were expressed as a 
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Post-drug threshold – Pre-drug threshold




For repetitive administration, the injection cannula was inserted, and an 
initial injection (5 or 50 nmol of 5IA dissolved in 5 μL of saline or vehicle) was 
performed using the method described above. A second injection of the same 
dose as that initially used was given 70 min later. Both groups consisted of four 
animals. Just before and 15, 30, 60, 85, 100, 130, and 160 min after the initial 
injection, tactile allodynia of the ligated paws was evaluated using the von Frey 
filament test, and %MPE values were calculated. 
 
Autoradiographic study 
For calculation of receptor occupancy, allodynia-expressing rats received 
an i.c.v. injection containing 370 kBq of [
125
I]5IA with a vehicle or various 
concentrations of 5IA (1, 3, 5, 10, 50, and 100 nmol) concomitantly (n = 5–6 in 
each group). The injected volume was 5 μL. Fifteen or 90 min later, they were 
decapitated. Their brains were quickly removed, frozen in hexane (–80°C), and 
cut into 20 μm-thick coronal sections with a cryostat (JUNG CM3000, Leica 
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Microsystems GmbH, Wetzlar, Germany). Autoradiograms were obtained, and 
quantitative analyses were performed according to a previously reported method 
(Kudo et al., 2009; Ueda et al., 2010). The data were expressed as a percentage 
of injected doses per gram of tissue (%ID/g) based on the data derived from 
125
I 
autoradiographic microscale standards (Amersham Biosciences, 
Buckinghamshire, UK). Regions of interest were drawn over the thalamus, and 
the accumulated total radioactivity (%ID/gT) was determined. Nonspecifically 
accumulated radioactivity (%ID/gNS) was also determined using rats that were 
administered (–)-cytisine (1 mg/kg, 200 μL) intravenously for 5 min prior to i.c.v. 
injection of [
125
I]5IA. The binding of [
125
I]5IA was completely blocked by 
administering (–)-cytisine via this route in our previous study (Saji et al., 2002). 
For the time course study of [
125
I]5IA accumulation in the thalamus, 
normal rats received an i.c.v. injection containing 370 kBq/5 μL of [125I]5IA (n = 
5–6 in each group). Five, 15, 30, 60, and 90 min later, they were decapitated, and 




 Receptor occupancy was calculated as per previous reports (Liu et al., 
2009; Miller et al., 2009) with a slight modification. The previous reports 
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regarded binding of the probes in the reference region as nonspecific binding. 
However, in lacking an nAChR reference region, we used (–)-cytisine 
overloading to quantify the nonspecific binding of [
125
I]5IA. The specific 
accumulation (%ID/gS) of [
125
I]5IA in the thalamus was obtained by subtracting 
the nonspecific accumulation from the corresponding total accumulation 
(%ID/gT – %ID/gNS). The specific accumulation to nonspecific accumulation 
ratio (SNR) was determined by dividing the specific accumulation by the 
nonspecific accumulation (%ID/gS / %ID/gNS). The receptor occupancy rate was 








 Analyses of the data from the von Frey filament test were performed 
using two-way analysis of variance (ANOVA) with repeated measures. If there 
was a significant difference, post hoc one-way ANOVA followed by the 
Tukey-Kramer multiple comparison test was performed using each treatment 
combination as an independent group. Correlation coefficients were assessed 
with Spearman rank correlation coefficients. Differences were considered 





Antiallodynic effect of single administration of 5IA 
 Paw withdrawal thresholds decreased from 12.2 ± 1.3 g to 3.4 ± 0.4 g in 
ligated paws. Effects of i.c.v. administeration of 5IA on paw withdrawal 
thresholds are shown in Fig 1. Two-way ANOVA demonstrated significant main 
effects of treatment (F6, 118 = 4.55, P = 0.002) and time (F3, 118 = 24.2, P < 0.001), 
and a significant interaction between treatment and time (F18, 118 = 3.10, P < 
0.001). A significant and dose-dependent antiallodynic effect was observed 15 
min and 30 min after administration (vehicle: 3 ± 6, 50 nmol: 62 ± 17, 100 nmol: 
65 ± 15 at 15 min). On the other hand, the effects were disappeared 90 min after 
administration (vehicle: –2 ± 3, 100 nmol: –1 ± 3) (Fig. 1). 
 
Relationship between thalamic nAChR occupancy by 5IA and antiallodynic 
effect 
  The time course study revealed that the specific accumulation of 
[
125
I]5IA in the thalamus increased in a time-dependent manner, and reached a 
plateau (1.5 ± 0.3% ID/g) at 30 min after administration. Next, thalamic nAChR 
occupancy by 5IA was determined 15 min and 90 min after i.c.v. administration. 
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The results are shown in Table 1. Both nAChR occupancy rates and 
antiallodynic effect reached a plateau at 50 or 100 nmol of 5IA. Fig. 2 shows a 
relationship between nAChR occupancy and antiallodynic effect at 15 min after 
i.c.v. administration, revealing a high positive correlation between them (r = 
0.97, P < 0.05). On the other hand, receptor occupancy rates did not decrease at 
90 min after administration, although the antiallodynic effects were disappeared. 
 
Antiallodynic effect of repetitive administered 5IA 
 We administered 5IA at 0 and 70 min, and performed the von Frey 
filament test. Two-way ANOVA demonstrated significant main effects of 
treatment (F2, 63 = 14.5, P = 0.002) and time (F6, 63 = 7.48, P < 0.001), and a 
significant interaction between treatment and time (F12, 63 = 6.73, P < 0.001). 
When administered 5 nmol of 5IA, which occupied about 40% of nAChRs in the 
thalamus, a significant antiallodynic effect was observed at 15 min (vehicle: –5 
± 5, 5 nmol: 21 ± 2). The effect diminished completely at 60 min (vehicle: 0.1 ± 
4, 5 nmol: 1 ± 4). Fifteen minutes after the second administration at 70 min, a 
significant antiallodynic effect was observed again (vehicle: –1 ± 7, 5 nmol: 35 
± 7).  
When 50 nmol of 5IA was administered, which occupied approximately 
80% of nAChRs in the thalamus, a significant antiallodynic effect was also 
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found at 15 min (50 nmol: 51 ± 5), and the effect decreased at 60 min (50 nmol: 
2 ± 2). In contrast to the significant antiallodynic effects observed after both the 
initial and second administration of 5 nmol of 5IA, repetitive administration of 
50 nmol of 5IA did not produce an antiallodynic effect at 85 min (15 min after 




Numerous studies have shown the antinociceptive effects of nicotine in a 
variety of preclinical pain models (Iwamoto and Marion, 1993; Jain, 2004; 
Kiguchi et al., 2008). However, antinociception in animals has been typically 
found to be of limited duration and attenuated with repeated dosing (Decker et 
al., 2004). Epibatidine also has been found to have a relatively short duration of 
action, with a substantial decay in effects observed within the first 30 min after 
administration—although it is a very potent antinociceptive agent with 
broad-spectrum activity (Gilbert et al., 2001). Antinociceptive effects of other 
nAChR agonists (A-85380 and ABT-594) have also been found to diminish until 
120 min after administration (Bannon et al., 1998; Rueter et al., 2003). Thus, the 
relatively short duration of action has been suggested as a common problem of 
nAChR agonists. 
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In the present study, we demonstrated a dose-dependent antiallodynic 
effect of 5IA 15 min after i.c.v. administration. The effect disappeared 60 min or 
90 min after administration. These results are consistent with our previous report. 
Since the maximum antiallodynic effect was observed 15 min after 
administration, we measured receptor occupancy rates at the same time point and 
compared them with each other. In result, a high positive correlation was 
observed between them in the thalamus (Fig. 2). This result is consistent with 
our previous finding that the nAChRs expressed in the thalamus mediated the 
antiallodynic effect (Ueda et al., 2010). 
We then attempted to explore the reason why the antiallodynic effect of 
5IA disappeared at 90 min after administration. The examination of temporal 
changes in thalamic [
125
I]5IA accumulation revealed that, rather than decreasing, 
[
125
I]5IA accumulation increased in a time-dependent manner, reaching a plateau 
at 30 min. Furthermore, the receptor occupancy rates at 90 min tended to be 
greater than those at 15 min (Table 1). A time-dependent clearance from the 
thalamus of 5IA not bound to nAChRs may be responsible for the increase in 
receptor occupancy rates. These results demonstrated that 5IA continues binding 
to nAChRs in the thalamus for at least 90 min after i.c.v. administration. Thus, 
the disappearance of antiallodynic effects was not due to the clearance of 5IA 
from the thalamus. 
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It is well known that nAChRs can undergo desensitization, a reversible 
reduction in response during sustained agonist application. Buisson et al. found 
that recovery from epibatidine-induced desensitization is very slow using a cell 
line stably expressed nAChRs. The authors suggested that epibatidine may have 
remained tightly bound to nAChRs in a non-activatable state because of its 
extremely high affinity (Buisson et al., 2000). In an in vivo experiment, the 
repetitive administration of epibatidine intrathecally within 30 min actually 
resulted a significant reduction of apparent antinociceptive effects (Khan et al., 
1998). Thus, epibatidine may induce desensitization of nAChRs by binding to 
them persistently in vivo.  
For this reason, we examined the possibility of desensitization of 
nAChRs caused by the persistent binding of 5IA. The similarity between 5IA 
and [
125
I]5IA is an appropriate property to use for deciding on the two doses of 
5IA: one is the dose used to produce a significant antiallodynic effect with full 
receptor occupancy; and the other is the dose used to produce a significant 
antiallodynic effect with leaving unoccupied nAChRs. Based on the results 
shown in Fig. 2, we decided on the following two dosages: a dose of 5 nmol, 
which had shown half-maximal occupancy rates; and a dose of 50 nmol, which 
had shown the maximal occupancy rates. When administered 5 nmol of 5IA, 
approximately 50% of nAChRs in the thalamus were occupied 90 min after the 
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initial administration. Therefore, 50% of the nAChRs in the thalamus probably 
existed still free at the second administration. With these unoccupied nAChRs, 
5IA could bind them and produce an antiallodynic effect again after the second 
administration. Conversely, 50 nmol of 5IA already occupied 80% of the 
nAChRs, with almost all the receptors kept occupying and temporarily inactive 
at the second administration. There were probably few available nAChRs in the 
thalamus; and thus, the second 5IA administration could not produce a 
significant effect. 
 Many studies have shown that α4-subunit-containing nAChRs, probably 
α4β2 nAChRs, play an important role in nAChR-mediated antinociception 
(Bitner et al., 1998; Bitner et al., 2000; Marubio et al., 1999). Since it has been 
reported that α4β2 nAChRs desensitize slowly (in terms of seconds) but are very 
prone to desensitization (Giniatullin et al., 2005), the relatively short duration of 
the antiallodynic effect produced by nAChR agonists was accounted for by the 
desensitization of α4β2 nAChRs. This suggests that there may be therapeutic 
benefits of positive allosteric modulators (PAMs) of α4β2 nAChRs, although 
the therapeutic potential of α4β2 nAChRs has been amply documented through 
use of selective agonists (Decker et al., 2004; Jain, 2004; Rowbotham et al., 
2009). PAMs would not be expected to induce cumulative receptor 
desensitization and should act in a manner consistent with the timing and 
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localization of endogenous cholinergic neurotransmission. For such reasons, the 
research efforts of pharmaceutical companies are now also focused on PAMs 
(Changeux, 2010; Taly et al., 2009). 
The involvement of α7 nAChRs in antinociceptive effects is controversial. 
Some studies have found α7-nAChR ligands to be efficacious (Young et al., 
2008) while others have not (Gao et al., 2010). Muhkin et al. reported that the 
α7/α4β2 affinity ratio of 5IA, calculated from the Ki value, was 25,000, 
indicating a high selectivity of 5IA for α4β2 nAChRs (Mukhin et al., 2000). 
Perry et al. have reported that nAChRs expressed in the thalamus are mainly of 
the α4β2 subtype (Perry et al., 2002), and thus the antiallodynic effect observed 
when 5IA bound to thalamic nAChRs was probably mediated via α4β2 nAChRs. 
However, 5IA might act on α7 and/or other nAChRs expressed in extrathalamic 
(central) or peripheral regions after the systemic administration of large doses in 
vivo. Relationships between receptor occupancy rates in these regions and 
antiallodynic effects remain uncertain. 
In summary, we measured the thalamic nAChR occupancy rates by 5IA in 
the PSL model of neuropathic pain, and then compared them to antiallodynic 
effects. A significant and dose-dependent antiallodynic effect was observed 15 
min after i.c.v. administration of 5IA. It was highly correlated with receptor 
occupancy rates, consistent with our previous finding that nAChRs expressed in 
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the thalamus mediate the antiallodynic effect. On the other hand, the 
antiallodynic effect was diminished in a short time, although thalamic nAChRs 
were kept occupying by 5IA 90 min after administration. A low dose of 5IA 
(which showed low receptor occupancy rates) exhibited a significant 
antiallodynic effect after the second administration, while a high dose of 5IA 
(which occupied almost all the thalamic nAChRs) showed no effect. These 
findings suggest that not clearance of 5IA but desensitization of nAChRs caused 
by persistent binding of 5IA is responsible for the disappearance of the 
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Table 1. Thalamic nAChR occupancy by 5IA after i.c.v. administraion 
dose (nmol) %RO at 15 min %RO at 90 min 
1 14 ± 7.1 n.d. 
3 22 ± 8.8 n.d. 
5 41 ± 21 55 ± 1.4 
10 63 ± 10 n.d. 
50 79 ± 7.0 94 ± 1.3 
100 81 ± 6.9 99 ± 0.5 
Data represent the mean ± SEM for five to six animals per group. 


































Effects of multiple doses of 5IA on neuropathic tactile allodynia. 5IA was 
administered i.c.v. at time 0. Data are presented as a percentage of maximum 
possible effect (% MPE). Each point represents the mean ± SEM of ligated paws 
of four to six animals per group. *P < 0.05, **P < 0.01 vs. vehicle, #P < 0.05 vs. 

































Correlation between antiallodynic effect and receptor occupancy at 15 min after 
i.c.v. administration of 5IA. The ordinate indicates the antiallodynic effect of 
multiple doses of 5IA and the abscissa indicates thalamic nAChR occupancy by 
the same doses of 5IA. The number in parentheses is the amount of 5IA 
administered. Each point represents the mean for four to six animals per group. 
The correlation coefficient (r) is 0.97, indicating a significant high correlation (P 















Antiallodynic effect of 5IA on neuropathic tactile allodynia after repetitive i.c.v. 
administration. The arrow indicates the time point of second administration (70 
min after first administration). Data are presented as a percentage of maximum 
possible effect (% MPE). Each point represents the mean ± SEM of the ligated 
paws of four animals per group. *P < 0.05, **P < 0.01 vs. vehicle, #P < 0.05, 
##P < 0.01 vs. 50 nmol of 5IA at the same time point. 
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